The human fibrinogen concentrate market is on a steady growth propelled by several pivotal factors. There is rise in global incidence of bleeding disorders necessitating the utilization of human ...
The FDA has approved a new fibrinogen concentrate — fibrinogen, human-chmt (Fesilty, Grifols Therapeutics, LLC) — for the treatment of acute bleeding episodes in pediatric and adult patients with ...
One of the primary fibrinogen concentrate market trends driving demand is the improved detection of congenital and acquired bleeding disorders. Enhanced diagnostic protocols, including genetic testing ...
PARAMUS, N.J., Jan. 7, 2026 /PRNewswire/ -- Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation of Fibryga ®, Fibrinogen (Human ...
Is fibrinogen concentrate useful for bleeding in high-risk cardiac surgery? In a study conducted in The Netherlands, [1] 647 patients (from 2011 to 2015) scheduled to have high-risk cardiac surgery ...
PARAMUS, N.J.--(BUSINESS WIRE)--Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga ®, Fibrinogen (Human) Lyophilized Powder for Reconstitution ...
Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development A couple of essential biomolecules play a key ...
EQS-News: Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...
Image by Zherebetskyy - Using Vesta visualisation software plotted the developed model similar to the Science paper, CC BY-SA 3.0 Image by Zherebetskyy - Using Vesta visualisation software plotted the ...
HOBOKEN, N.J. (November 5, 2019) - Octapharma USA sponsored a scientific symposium, "Fibrinogen Supplementation in Surgical Patients - New Perspectives in Acquired Fibrinogen Deficiency," at the ...
LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorization to its new fibrinogen concentrate product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results